ArticleAlimentary pharmacology & therapeutics2026
Natural History of Recurrent Acute Pancreatitis: Implications for Interventional Trial Design.
Article in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Natural History of Recurrent Acute Pancreatitis: Implications for Interventional Trial Design.Alimentary pharmacology & therapeutics · 2026Article
- Editorial: Dissecting the Natural History of Recurrent Pancreatitis.Alimentary pharmacology & therapeutics · 2026Article
- Letter: Severity-Informed Enrichment for Recurrent Acute Pancreatitis Trials.Alimentary pharmacology & therapeutics · 2026Article
- Letter: Severity-Informed Enrichment for Recurrent Acute Pancreatitis Trials. Authors' Reply.Alimentary pharmacology & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with acute pancreatitis (AP) often experience recurrent acute pancreatitis (RAP), increasing the risk of chronic pancreatitis (CP) and long-term complications. Progression along the AP-RAP-CP spectrum has been explored in epidemiological studies, but available data provide limited insight into recurrence dynamics within RAP itself. This information is crucial for the design of studies aiming to prevent RAP recurrence and disease progression.
methodsIn this nationwide cohort study, we included 45,338 Danish adults hospitalised with an incident episode of AP between January 1, 2000, and December 31, 2022, identified through national health registries. RAP was defined as recurrent hospitalisations for AP separated by ≥ 90 days. Competing risk models with pseudo-observations estimated cumulative incidence functions for RAP recurrence stratified by the number of prior AP episodes. Inter-episode intervals were estimated using Weibull models.
resultsDuring a median follow-up of 4.5 years, 6894 patients developed RAP, corresponding to a 15.2% risk (95% confidence interval, 14.9%-15.5%). The RAP recurrence risk increased with accumulating episodes. The 12-month cumulative incidence of RAP recurrence rose from 17% after one RAP episode to 46% after five episodes. Most recurrences occurred within 12 months, and inter-episode intervals shortened with increasing episode number. Weibull models demonstrated a wear-out pattern, with shape parameters increasing progressively across successive RAP episodes, indicating accelerating recurrence risk over time.
conclusionsRAP follows an accelerating course characterised by increasing recurrence risk. Risk-enriched trial designs targeting patients with more prior episodes may improve the feasibility and statistical efficiency of future interventional studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.